BOTHELL, Wash., July 13 /PRNewswire-FirstCall/ -- Cardiac Science Corporation (Nasdaq: CSCX), a global leader in automated external defibrillator (AED) and diagnostic cardiac monitoring devices, today expands its ECG and cardiac stress product lines with CareCenter MD, a multimodality PC-based diagnostic workstation designed for today's physician practices.
"CareCenter MD delivers superior ease-of-use and efficiency," said Rene Mitchell, Cardiac Science director of marketing. "It's the first PC-based diagnostic workstation that supports both resting ECG and stress testing with a wireless data acquisition module. And, it allows physicians to comply with pending electronic record mandates even if they have not yet chosen an electronic medical record (EMR) partner."
The CareCenter MD diagnostic workstation features:
- Wireless data acquisition: A Bluetooth connection between the patient and the diagnostic workstation removes the need for cables, providing the opportunity for physicians to perform testing in a wider range of settings.
- Advanced connectivity: Physicians can read, analyze, and confirm patient tests from anywhere with a secure internet connection. While no EMR is required to view data with CareCenter MD, records can be easily transferred to an EMR if desired.
- Shared patient database: Data for both ECG and stress tests are stored in the same database and can be easily accessed and reviewed, allowing physicians to make real-time comparisons of historical versus current patient data.
- Modern user interface: A simple and intuitive interface featuring one-button navigation makes CareCenter MD easy-to-use, reducing the need for training and allowing fast and efficient workflow.
"This is another important new product for our cardiac monitoring business," said Dave Marver, Cardiac Science president and chief executive officer. "We are extending our leadership in primary care cardiology in 2010 with a series of technology introductions."
About Cardiac Science
Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AED), electrocardiograph devices (ECG/EKG), cardiac stress treadmill and systems, PC-based diagnostic workstations, Holter monitoring systems, hospital defibrillators, vital signs monitors, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The company sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick®, HeartCentrix®, Powerheart®, and Quinton® brands, is headquartered in Bothell, Washington. With customers in almost 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.
For updates and information on worldwide defibrillation and cardiac monitoring, find us on the Cardiac Science blog at http://www.cardiacscience.com/blog, Twitter at http://twitter.com/cardiacscience, Facebook at http://budurl.com/CSonFB, and YouTube at http://budurl.com/CSonYT.
This press release contains forward-looking statements. The word "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward looking statements in this press release include, but are not limited to, those that refer to product compliance with legal mandates, regulations or other applicable legal authority; the relative importance of one or more particular products to Cardiac Science's business or any portion of its business; and the anticipated future introduction of new technologies and products. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results and performance may vary significantly from those expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks include those more fully described in the Annual Report on Form 10-K filed by Cardiac Science Corporation for the year ended December 31, 2009, as updated by subsequent quarterly reports on Form 10-Q. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.
For more information,
Cardiac Science Corporation
Senior Vice President and CFO
Allen & Caron
EVC Group Inc.
SOURCE Cardiac Science Corporation